<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37429670</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000817</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000817</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess real-world treatment regimens and patterns in childhood-onset SLE (cSLE) and adult-onset SLE (aSLE) cohorts, including similarities in treatments, duration of use and adherence.</AbstractText><AbstractText Label="METHODS">This retrospective study utilised data from Merative L.P. MarketScan Research Databases (USA). Index date was the date of first SLE diagnosis (2010-2019). Patients aged &lt;18 years (cSLE) and &#x2265;18 years (aSLE) at index date with confirmed SLE diagnosis and &#x2265;12 months continuous enrolment during pre-index and post-index periods were included. The cohorts were stratified based on the presence (existing) or absence (new) of pre-index SLE. Primary outcomes (post-index period) included treatment regimens (all patients), and adherence (proportion of days covered (PDC)) and discontinuation of therapies initiated within 90 days of diagnosis (new patients). Univariate comparisons between cSLE and aSLE cohorts were performed using Wilcoxon rank-sum and &#x3c7;<sup>2</sup> (or Fisher's exact) tests.</AbstractText><AbstractText Label="RESULTS">cSLE cohort included 1275 patients (mean age=14.1 years) and aSLE cohort included 66&#x2009;326 patients (mean age=49.7 years). Antimalarials and glucocorticoids were commonly used among new (cSLE=64.4%/62.0%; aSLE=51.8%/49.7%) and existing (cSLE=68.6%/58.9%; aSLE=63.8%/51.3%) patients in both cohorts. Median oral glucocorticoid dose (prednisone equivalent) was higher in cSLE vs aSLE (new=22.1 vs 14.0&#x2009;mg/day; existing=14.4 vs 12.3&#x2009;mg/day; p&lt;0.05). Mycophenolate mofetil use was higher in patients with cSLE vs aSLE (new=26.2% vs 5.8%; existing=37.6% vs 11.0%; p&lt;0.0001). Compared with aSLE, more patients used combination therapies in cSLE (p&lt;0.0001). Median PDC was higher in cSLE vs aSLE for antimalarials (0.9 vs 0.8; p&lt;0.0001) and oral glucocorticoids (0.6 vs 0.3; p&lt;0.0001). Treatment discontinuation was lower in cSLE vs aSLE for antimalarials (25.0% vs 33.1%; p&lt;0.0001) and oral glucocorticoids (56.6% vs 71.2%; p&lt;0.0001).</AbstractText><AbstractText Label="CONCLUSIONS">Management of cSLE and aSLE includes the same medication classes; differences include more intensive use of therapy in cSLE, warranting the need for approved safe medications for cSLE.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Hermine I</ForeName><Initials>HI</Initials><Identifier Source="ORCID">0000-0001-9478-2987</Identifier><AffiliationInfo><Affiliation>Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vadhariya</LastName><ForeName>Aisha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1811-5370</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA vadhariya_aisha@lilly.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crandall</LastName><ForeName>Wallace</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kar-Chan Choong</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birt</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruperto</LastName><ForeName>Nicolino</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8407-7782</Identifier><AffiliationInfo><Affiliation>IRCCS Istituto Giannina Gaslini, UOC Gaslini Trial Centre/Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanan</LastName><ForeName>Athimalaipet V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Bristol Royal Hospital for Children, Bristol, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Health Sciences, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="Y">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune diseases</Keyword><Keyword MajorTopicYN="N">Healthcare outcome assessment</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Competing interests: HIB has received consulting fees from AbbVie, Astra Zeneca-Medimmune, Biogen, Boehringer, Bristol Myers Squibb, Celgene, Eli Lilly, EMD Serono, Idorsia, Cerocor, Janssen, GlaxoSmithKline, F Hoffmann-La Roche, Merck, Novartis, R-Pharm and Sanofi. The Cincinnati Children&#x2019;s Hospital, where HIB works as a full-time public employee, has received contributions from the following industries in the past 3 years: Bristol Myers Squibb, F Hoffmann-La Roche, Janssen, Novartis and Pfizer. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties. HIB has received speaking fees from Novartis, Pfizer and GlaxoSmithKline. CD, WC, CK-CC and JB are employees and stockholders of Eli Lilly and Company. AV is an employee of Eli Lilly and Company. NR has received honoraria for consultancies or speaker bureaus in the past 3 years from 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Bristol Myers and Squibb, Celgene, InMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi and UCB. NR has participated on a Data Safety Monitoring Board or Advisory Board for Pfizer and Eli Lilly. The IRCCS Istituto Giannina Gaslini (IGG), where NR works as a full-time public employee, has received contributions from the following industries in the last 3 years: Bristol Myers and Squibb, Eli Lilly, F Hoffmann-La Roche, Novartis, Pfizer and Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties. NR is the senior scientist unpaid of the Paediatric Rheumatology International Trials Organisation (PRINTO, www.printo.it). NR participates unpaid to a Data Safety and Monitoring Board of an investigator-initiated study. AVR has received consulting fees from Eli Lilly, UCB, AbbVie, Novartis, Roche and Alimera biosciences. AVR has received payment or honoraria from Eli Lilly, UCB, AbbVie, Novartis, Roche and Alimera biosciences. AVR has participated on a Data Safety Monitoring Board or Advisory Board for Eli Lilly.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37429670</ArticleId><ArticleId IdType="pmc">PMC10335505</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000817</ArticleId><ArticleId IdType="pii">10/2/e000817</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gordon C, Amissah-Arthur M-B, Gayed M, et al. . The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018;57:1502&#x2013;3. 10.1093/rheumatology/key170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key170</ArticleId><ArticleId IdType="pubmed">29893921</ArticleId></ArticleIdList></Reference><Reference><Citation>Toong C, Adelstein S, Phan TG. Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renovasc Dis 2011;4:17&#x2013;28. 10.2147/IJNRD.S10233</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJNRD.S10233</ArticleId><ArticleId IdType="pmc">PMC3108794</ArticleId><ArticleId IdType="pubmed">21694945</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarc&#xf3;n GS, Scofield L, et al. . Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257&#x2013;68. 10.1016/j.semarthrit.2008.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2008.10.007</ArticleId><ArticleId IdType="pmc">PMC2813992</ArticleId><ArticleId IdType="pubmed">19136143</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Gladman DD, Touma Z, et al. . Disease course patterns in systemic lupus erythematosus. Lupus 2019;28:114&#x2013;22. 10.1177/0961203318817132</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318817132</ArticleId><ArticleId IdType="pubmed">30526328</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Lythgoe H, Hedrich CM. Vasculitis in juvenile-onset systemic lupus erythematosus. Front Pediatr 2019;7:149. 10.3389/fped.2019.00149</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00149</ArticleId><ArticleId IdType="pmc">PMC6521594</ArticleId><ArticleId IdType="pubmed">31143758</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Lythgoe H, Midgley A, et al. . Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol 2019;209:108274. 10.1016/j.clim.2019.108274</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.108274</ArticleId><ArticleId IdType="pubmed">31678365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraki LT, Feldman CH, Liu J, et al. . Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 2012;64:2669&#x2013;76. 10.1002/art.34472</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34472</ArticleId><ArticleId IdType="pmc">PMC3564552</ArticleId><ArticleId IdType="pubmed">22847366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineles D, Valente A, Warren B, et al. . Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 2011;20:1187&#x2013;92. 10.1177/0961203311412096</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311412096</ArticleId><ArticleId IdType="pubmed">21768176</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, et al. . New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 2016;12:716&#x2013;30. 10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE--towards a comprehensive management plan. Nat Rev Rheumatol 2011;7:225&#x2013;33. 10.1038/nrrheum.2011.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2011.15</ArticleId><ArticleId IdType="pubmed">21386795</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Gladman DD, Iba&#xf1;ez D, et al. . Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008;58:556&#x2013;62. 10.1002/art.23204</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23204</ArticleId><ArticleId IdType="pubmed">18240232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Brunner HI. Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 2010;36:53&#x2013;80. 10.1016/j.rdc.2009.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2009.12.012</ArticleId><ArticleId IdType="pmc">PMC2837537</ArticleId><ArticleId IdType="pubmed">20202591</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al. . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736&#x2013;45. 10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravelli A, Duarte-Salazar C, Buratti S, et al. . Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 2003;49:501&#x2013;7. 10.1002/art.11205</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.11205</ArticleId><ArticleId IdType="pubmed">12910556</ArticleId></ArticleIdList></Reference><Reference><Citation>Miettunen PM, Pistorio A, Palmisani E, et al. . Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Ann Rheum Dis 2013;72:1503&#x2013;9. 10.1136/annrheumdis-2012-201937</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201937</ArticleId><ArticleId IdType="pubmed">23100607</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Egbivwie N, Jorgensen AL, et al. . Real world treatment of juvenile-onset systemic lupus erythematosus: data from the UK JSLE cohort study. Clin Immunol 2022;239:109028. 10.1016/j.clim.2022.109028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109028</ArticleId><ArticleId IdType="pubmed">35513304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. . Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20&#x2013;8. 10.1136/ard.2008.101766</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.101766</ArticleId><ArticleId IdType="pubmed">19103632</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N, de Graeff N, Avcin T, et al. . European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017;76:1788&#x2013;96. 10.1136/annrheumdis-2016-210960</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210960</ArticleId><ArticleId IdType="pubmed">28630236</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher KL, Patel P, Beresford MW, et al. . What have we learnt about the treatment of juvenile-onset systemic lupus erythematous since development of the SHARE recommendations 2012? Front Pediatr 2022;10:884634. 10.3389/fped.2022.884634</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.884634</ArticleId><ArticleId IdType="pmc">PMC9047745</ArticleId><ArticleId IdType="pubmed">35498799</ArticleId></ArticleIdList></Reference><Reference><Citation>Moores KG, Sathe NA. A systematic review of validated methods for identifying systemic lupus erythematosus (SLE) using administrative or claims data. Vaccine 2013;31 Suppl 10:K62&#x2013;73. 10.1016/j.vaccine.2013.06.104</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.06.104</ArticleId><ArticleId IdType="pubmed">24331075</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkema EV, J&#xf6;nsen A, R&#xf6;nnblom L, et al. . Case definitions in Swedish register data to identify systemic lupus erythematosus. BMJ Open 2016;6:e007769. 10.1136/bmjopen-2015-007769</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2015-007769</ArticleId><ArticleId IdType="pmc">PMC4716148</ArticleId><ArticleId IdType="pubmed">26729375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan HJ, Song X, Johnson BH, et al. . Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. Biomed Res Int 2013;2013:808391. 10.1155/2013/808391</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/808391</ArticleId><ArticleId IdType="pmc">PMC3591216</ArticleId><ArticleId IdType="pubmed">23484162</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz I, Choong C, Winnie J, et al. . Development of a claims-based flare algorithm for systemic lupus erythematosus. Curr Med Res Opin 2022;38:1641&#x2013;9. 10.1080/03007995.2022.2101804</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2101804</ArticleId><ArticleId IdType="pubmed">35866412</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler AM, Nickel KB, Overman RA, et al. . IBM Marketscan research databases. In: Sturkenboom M, Schink T, eds. Databases for Pharmacoepidemiological Research. Cham: Springer International Publishing, 2021: 243&#x2013;51.</Citation></Reference><Reference><Citation>Hansen L. White paper: IBM marketscan research databases for life sciences researchers. 2019. Available: https://www.ibm.com/downloads/cas/0NKLE57Y</Citation></Reference><Reference><Citation>Pharmacy Quality Alliance (PQA) . PQA measure overview. 2019. Available: https://www.pqaalliance.org/adherence-measures [Accessed 22 Oct 2022].</Citation></Reference><Reference><Citation>Nau . Proportion of days covered (PDC) as a preferred method of measuring medication adherence. 2011. Available: https://sep.yimg.com/ty/cdn/epill/pdcmpr.pdf [Accessed 22 Oct 2022].</Citation></Reference><Reference><Citation>World Health Organization . Adherence to long-term therapies: evidence for action. 2003. Available: https://apps.who.int/iris/handle/10665/42682 [Accessed 22 Oct 2022].</Citation></Reference><Reference><Citation>Davis A, Chang J, Shapiro S, et al. . Immunomodulatory medication use in newly diagnosed youth with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2021;73:1672&#x2013;7. 10.1002/acr.24392</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24392</ArticleId><ArticleId IdType="pmc">PMC9212072</ArticleId><ArticleId IdType="pubmed">32702144</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JC, Costenbader KH. Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus. Semin Arthritis Rheum 2022;56:152042. 10.1016/j.semarthrit.2022.152042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152042</ArticleId><ArticleId IdType="pmc">PMC9724699</ArticleId><ArticleId IdType="pubmed">35738041</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JC, Knight AM, Lawson EF. Patterns of healthcare use and medication adherence among youth with systemic lupus erythematosus during transfer from pediatric to adult care. J Rheumatol 2021;48:105&#x2013;13. 10.3899/jrheum.191029</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.191029</ArticleId><ArticleId IdType="pmc">PMC7394721</ArticleId><ArticleId IdType="pubmed">32007936</ArticleId></ArticleIdList></Reference><Reference><Citation>Trindade VC, Carneiro-Sampaio M, Bonfa E, et al. . An update on the management of childhood-onset systemic lupus erythematosus. Paediatr Drugs 2021;23:331&#x2013;47. 10.1007/s40272-021-00457-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40272-021-00457-z</ArticleId><ArticleId IdType="pmc">PMC8270778</ArticleId><ArticleId IdType="pubmed">34244988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardoin SP, Daly RP, Merzoug L, et al. . Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J 2019;17:32. 10.1186/s12969-019-0327-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-019-0327-4</ArticleId><ArticleId IdType="pmc">PMC6600895</ArticleId><ArticleId IdType="pubmed">31262324</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon L, Caliendo A, Hersh A, et al. . "There's so much to be done": a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus. Lupus Sci Med 2022;9:e000659. 10.1136/lupus-2022-000659</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000659</ArticleId><ArticleId IdType="pmc">PMC8971800</ArticleId><ArticleId IdType="pubmed">35361711</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Martini A, Lovell DJ, et al. . Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Ann Rheum Dis 2019;78:162&#x2013;70. 10.1136/annrheumdis-2018-213198</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213198</ArticleId><ArticleId IdType="pubmed">30232192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh AO, von Scheven E, Yazdany J, et al. . Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009;61:13&#x2013;20. 10.1002/art.24091</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24091</ArticleId><ArticleId IdType="pmc">PMC2875186</ArticleId><ArticleId IdType="pubmed">19116979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui-Yuen JS, Imundo LF, Avitabile C, et al. . Early versus later onset childhood-onset systemic lupus erythematosus: clinical features, treatment and outcome. Lupus 2011;20:952&#x2013;9. 10.1177/0961203311403022</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311403022</ArticleId><ArticleId IdType="pubmed">21676918</ArticleId></ArticleIdList></Reference><Reference><Citation>Heshin-Bekenstein M, Trupin L, Yelin E, et al. . Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2019;49:267&#x2013;72. 10.1016/j.semarthrit.2019.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.05.010</ArticleId><ArticleId IdType="pmc">PMC7480934</ArticleId><ArticleId IdType="pubmed">31235075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Smith J, Brunner HI. Update on the treatment and outcome of systemic lupus erythematous in children. Curr Opin Rheumatol 2019;31:464&#x2013;70. 10.1097/BOR.0000000000000621</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000621</ArticleId><ArticleId IdType="pubmed">31107290</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JG, Maletta KI, Kuhn EM, et al. . Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients. Clin Rheumatol 2017;36:351&#x2013;9. 10.1007/s10067-016-3518-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-016-3518-0</ArticleId><ArticleId IdType="pubmed">28013435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollander MC, Sage JM, Greenler AJ, et al. . International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013;65:1416&#x2013;23. 10.1002/acr.21998</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21998</ArticleId><ArticleId IdType="pubmed">23463586</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration . Lupus therapies continue to evolve. 2021. Available: https://www.fda.gov/consumers/consumer-updates/lupus-therapies-continue-evolve [Accessed 06 Jun 2023].</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration . FDA approves first treatment for pediatric patients with lupus. 2019. Available: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-pediatric-patients-lupus [Accessed 06 Jun 2023].</Citation></Reference><Reference><Citation>Mahmoud I, Jellouli M, Boukhris I, et al. . Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review. J Pediatr 2017;187:213&#x2013;9. 10.1016/j.jpeds.2017.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2017.05.002</ArticleId><ArticleId IdType="pubmed">28602379</ArticleId></ArticleIdList></Reference><Reference><Citation>Semo-Oz R, Wagner-Weiner L, Edens C, et al. . Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. Lupus 2022;31:1508&#x2013;15. 10.1177/09612033221115974</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221115974</ArticleId><ArticleId IdType="pubmed">35938626</ArticleId></ArticleIdList></Reference><Reference><Citation>Harry O, Crosby LE, Smith AW, et al. . Self-management and adherence in childhood-onset systemic lupus erythematosus: what are we missing? Lupus 2019;28:642&#x2013;50. 10.1177/0961203319839478</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319839478</ArticleId><ArticleId IdType="pmc">PMC6506349</ArticleId><ArticleId IdType="pubmed">30907294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>